For research teamsHelp me find a study
Back to all studies
CompletedNCT00640601

Effectiveness of SEROQUEL XR® (Quetiapine Fumarate Extended-Release Tablets) in schizophrenia

This study is completed in Australia, in Canada, in China, .... It is testing SEROQUEL XR® (Quetiapine Fumarate Extended-Release Tablets) for schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore recruiting studies on this topic

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What is this study testing?

This study is testing whether Study Evaluating the Clinical Benefit of SEROQUEL XR may be useful for adults experiencing schizophrenia.

What would participation involve?

Participants may receive Study Evaluating the Clinical Benefit of SEROQUEL XR, attend study visits with the research team. The registry lists locations in Australia, in Canada, and in China.

Who is it mainly for?

This study appears to be mainly for adults with schizophrenia.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)

  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateMarch 2008
Recruitment status
Completed
Enrollment listed in the registry
331
Sponsor
AstraZeneca
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Australia, Canada, China, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT00640601
Official title
A Multicentre, Open-label, Prospective Long-term Study Evaluating the Clinical Benefit and Effectiveness of SEROQUEL XR® (Quetiapine Fumarate Extended-Release Tablets) in Subjects With Schizophrenia

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT00640601. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

Australia · 5 sites
  • Research Site
    Garran, Australian Capital Territory
    Site status: Not listed — confirm with the team
  • Research Site
    Newcastle, New South Wales
    Site status: Not listed — confirm with the team
  • Research Site
    Brisbane, Queensland
    Site status: Not listed — confirm with the team
  • Research Site
    Meadowbrook, Queensland
    Site status: Not listed — confirm with the team
  • Research Site
    Dandenong, Victoria
    Site status: Not listed — confirm with the team
Canada · 29 sites
  • Research Site
    Calgary, Alberta
    Site status: Not listed — confirm with the team
  • Research Site
    Claresholm, Alberta
    Site status: Not listed — confirm with the team
  • Research Site
    Red Deer, Alberta
    Site status: Not listed — confirm with the team
  • Research Site
    Vancouver, British Columbia
    Site status: Not listed — confirm with the team
  • Research Site
    Victoria, British Columbia
    Site status: Not listed — confirm with the team
  • Research Site
    Miramichi, New Brunswick
    Site status: Not listed — confirm with the team
  • Research Site
    St. John's, Newfoundland and Labrador
    Site status: Not listed — confirm with the team
  • Research Site
    Sydney, Nova Scotia
    Site status: Not listed — confirm with the team
  • Research Site
    Belleville, Ontario
    Site status: Not listed — confirm with the team
  • Research Site
    Brantford, Ontario
    Site status: Not listed — confirm with the team
  • Research Site
    Chatham, Ontario
    Site status: Not listed — confirm with the team
  • Research Site
    Cornwall, Ontario
    Site status: Not listed — confirm with the team
  • Research Site
    Greater Sudbury, Ontario
    Site status: Not listed — confirm with the team
  • Research Site
    London, Ontario
    Site status: Not listed — confirm with the team
  • Research Site
    Markham, Ontario
    Site status: Not listed — confirm with the team
  • Research Site
    Mississauga, Ontario
    Site status: Not listed — confirm with the team
  • Research Site
    Newmarket, Ontario
    Site status: Not listed — confirm with the team
  • Research Site
    Oakville, Ontario
    Site status: Not listed — confirm with the team
  • Research Site
    Orléans, Ontario
    Site status: Not listed — confirm with the team
  • Research Site
    Toronto, Ontario
    Site status: Not listed — confirm with the team
  • Research Site
    Windsor, Ontario
    Site status: Not listed — confirm with the team
  • Research Site
    Gatineau, Quebec
    Site status: Not listed — confirm with the team
  • Research Site
    Greenfield Park, Quebec
    Site status: Not listed — confirm with the team
  • Research Site
    Montreal, Quebec
    Site status: Not listed — confirm with the team
  • Research Site
    Québec, Quebec
    Site status: Not listed — confirm with the team
  • Research Site
    Rouyn-Noranda, Quebec
    Site status: Not listed — confirm with the team
  • Research Site
    Verdun, Quebec
    Site status: Not listed — confirm with the team
  • Research Site
    Prince Albert, Saskatchewan
    Site status: Not listed — confirm with the team
  • Research Site
    Saskatoon, Saskatchewan
    Site status: Not listed — confirm with the team
Hong Kong · 1 site
  • Research Site
    Hong Kong
    Site status: Not listed — confirm with the team
South Korea · 1 site
  • Research Site
    Seoul, Korea
    Site status: Not listed — confirm with the team
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving Quetiapine Fumarate Extended- Release. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.

Who might this study be for?

This study may concern people with schizophrenia; age range: From 18 Years to 65 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by AstraZeneca, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.